相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Viral vectors as vaccine platforms: deployment in sight
Christine S. Rollier et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria
Arturo Reyes-Sandoval et al.
JOURNAL OF IMMUNOLOGY (2011)
Prime-boost vectored malaria vaccines Progress and prospects
Adrian V. S. Hill et al.
HUMAN VACCINES (2010)
Advances and challenges in malaria vaccine development
Peter D. Crompton et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens
David M. Asmuth et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
Laurence Peiperl et al.
PLOS ONE (2010)
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
J. E. Ledgerwood et al.
VACCINE (2010)
Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
Stefania Capone et al.
VACCINE (2010)
Extreme CD8 T Cell Requirements for Anti-Malarial Liver-Stage Immunity following Immunization with Radiation Attenuated Sporozoites
Nathan W. Schmidt et al.
PLOS PATHOGENS (2010)
Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy
M. Dudareva et al.
VACCINE (2009)
Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
Arturo Reyes-Sandoval et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Susan P. Buchbinder et al.
LANCET (2008)
Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
Philip Bejon et al.
PLOS ONE (2007)
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
Philip Bejon et al.
PLOS CLINICAL TRIALS (2006)
A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
S. J. Dunachie et al.
INFECTION AND IMMUNITY (2006)
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
DP Webster et al.
VACCINE (2006)
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria
SM Keating et al.
JOURNAL OF IMMUNOLOGY (2005)
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
DP Webster et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites
P Bejon et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
VS Moorthy et al.
PLOS MEDICINE (2004)
Adenoviruses as vaccine vectors
N Tatsis et al.
MOLECULAR THERAPY (2004)
分享论文
